首页> 美国卫生研究院文献>International Journal of Proteomics >The Application of a Three-Step Serum Proteome Analysis for the Discovery and Identification of Novel Biomarkers of Hepatocellular Carcinoma
【2h】

The Application of a Three-Step Serum Proteome Analysis for the Discovery and Identification of Novel Biomarkers of Hepatocellular Carcinoma

机译:三步血清蛋白质组学分析在发现和鉴定肝细胞癌新型生物标志物中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The representative tumor markers for HCC, AFP, and PIVKA-II are not satisfactory in terms of sensitivity and specificity in the early diagnosis of HCC. In search for novel markers for HCC, three-step proteome analyses were carried out in serum samples obtained from 12 patients with HCC and 10 with LC. As a first step, serum samples were subjected to antibody-based immunoaffinity column system that simultaneously removes twelve of abundant serum proteins. The concentrated flow-through was then fractionated using reversed-phase HPLC. Proteins obtained in each fraction were separated by SDS-PAGE. Serum samples obtained from patient with HCC and with LC were analyzed in parallel and their protein expression patterns were compared. A total of 83 protein bands were found to be upregulated in HCC serum. All the protein bands, the intensity of which was different between HCC and LC groups, were identified. Among them, clusterin was most significantly overexpressed (P = 0.023). The overexpression of serum clusterin was confirmed by ELISA using another validation set of HCC samples. Furthermore, serum clusterin was elevated in 40% of HCC cases in which both AFP and PIVKA-II were within their cut-off values. These results suggested that clusterin is a potential novel serum marker for HCC.
机译:HCC,AFP和PIVKA-II的代表性肿瘤标志物在HCC早期诊断的敏感性和特异性方面并不令人满意。为了寻找新的肝癌标记物,对从12例HCC患者和10例LC患者中获得的血清样本进行了三步蛋白质组分析。第一步,对血清样品进行基于抗体的免疫亲和柱系统,该系统可同时去除十二种丰富的血清蛋白。然后使用反相HPLC分级浓缩浓缩液。通过SDS-PAGE分离每个级分中获得的蛋白质。平行分析从HCC和LC患者获得的血清样本,并比较其蛋白表达模式。发现总共83条蛋白带在HCC血清中被上调。鉴定出所有蛋白条带,其强度在HCC组和LC组之间不同。其中,簇蛋白表达最明显(P = 0.023)。使用另一套验证的HCC样品通过ELISA证实了血清簇蛋白的过表达。此外,在AFP和PIVKA-II都在其临界值范围内的HCC病例中,血清簇蛋白升高。这些结果表明簇蛋白是潜在的新型肝癌血清标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号